
#### **Hospital Authority Convention 2016**

Integrated Chinese-Western Medicine Pilot Programme Department of Clinical Oncology, Tuen Mun Hospital

## Integrated Chinese-Western Medicine Pilot Programme

#### Dr. S.H. LO

**Consultant, Department of Clinical Oncology Tuen Mun Hospital** 







# **Objectives of the Pilot Program**

- To utilize ICWM for maximizing patient care
- To gain experience for facilitating the development of Chinese Medicine(CM) in-patient service and hospital
- To facilitate postgraduate CM development and training






## Implementation

- The Integrated Chinese-Western Medicine (ICWM) Pilot Programme has been started in 3 hospitals (TWH, PYNEH & TMH) on 22<sup>nd</sup> Sept 2014.
- The Phase 2 ICWM pilot project implementation on 21<sup>st</sup> Dec 2015.

	Hospital	CMCTR	Phase I	Phase II
Cancer	ТМН	YOT	✓	$\checkmark$
Palliative Care	РМН	НКС		$\checkmark$
Acute Low	PYNEH	ED	✓	$\checkmark$
Back Pain Care	КШН	HMT		$\checkmark$
Stroke Care	ТѠН	TW	✓	$\checkmark$
	PWH/SH	ST		$\checkmark$





- Chinese Medicine Centre for Training & Research operated by
  - Hospital Authority
  - University
  - NGO





#### Governance

- Task force on the Development of ICWM •
- Clinical Working Groups on Stroke Care, Cancer Palliative Care & Musculoskeletal Pain Care for development of evidence-based clinical protocols
- **Operational Working Group** ٠
- Expert Panel on CM safety for ICWM Pilot Projects ۰
- Programme Audit Working Group
- **Cluster ICWM Committees**
- **Financial Audits**
- **Evaluation Studies**





### **Develop the Protocol**



# Standards/ Guidelines Developed or Revised

Ŷ	Hospital Author	ity Head Office	Document No. Issue Date Review Date	13/2008 26 September 2014 September 2017
R R T R N	專科集团服務担引一中醫議組		Review Date Approved by Page	September 2017 COC-G(N) 1 of 21
		獲理服務 醫護3	Ser Disease	
		P 西 醫 協 作 先 導 計 劃		
		2014 - 2016		
	Version	Effective Date		
	1.0	27 November 20	08	
	2.0	26 September 20	014	
D	ocument Number	COC-G(N) App		
	Author	SAG(Tradition		dicine)
_	Custodian		D/HOCS	4
	Approved By		DC-G(N)	
-	Approver Approval Date		Signed)	
1	Abbiogai Date	,	ending	

Department of Clinical Oncology, Tuen Mun Hospital

Hospital Authority Convention 2016

WKKL

## Training

Year	Training course	Course duration
2014-2015	中醫專科護理	中醫護理基礎 (36 小時) 中醫專科護理 (30 小時) 中醫專科護理藥用及技術(24小時)
	Certificate in CM Training Program for Medical and Healthcare Professional (SPACE)	Theory (102 hours) Practicum (16 hours)
	Briefing session for ICWM pilot program	Protocol training on CM treatment plan - 4 hours Workshop on operational procedure - 3 hours
	海外培訓:廣東省中醫院 中醫護理訓練	4 weeks Corporate Overseas Training
	Commissioned Seminars: Fundamental in Stroke, Cancer and Pain Management in TCM Perspectives	6 whole day (42 hours)
	Certificate in CM Training Program for Medical and Healthcare Professional(SPACE)	Theory (92 hours) Practicum (12 hours)
2015-2016	Intermediate Chinese Medicine Training Programme in Nursing Care 2015 (OUHK)	Theory (45 hours) Practicum (16 hours)
	Commissioned Seminars: Non-invasive TCM Nursing Practice for Pain Management, Insomnia, Nausea, Cold Intolerance, Vertigo and Fatigue	6 whole day (42 hours)
	海外培訓:廣東省中醫院中醫護理訓練	4 weeks Corporate Overseas Training





#### **Overseas Corporate Scholarship Program for Clinical Leaders 2014/15 & 2015/16**



培訓內容


時間	第一個星期	第二個星期	第三個星期	第四個星期
培訓 內容	<ul> <li>中央護理部報到</li> <li>腫瘤科</li> <li>腫瘤科座談會</li> <li>骨科</li> <li>参觀護士學生考試</li> <li>護理程序座談會</li> </ul>	<ul> <li> <ul> <li> • 針灸科 </li> <li> • 傳統療法中心 </li> <li> • 大學城分院肝病科 </li> <li> • 中醫藥博物館 </li> <li> · 治未病中心 </li> </ul></li></ul>	<ul> <li>練習各種中醫護理 操作</li> <li>觀摩中醫院首屆個 案護理展示大賽</li> <li>二沙島分院婦科、 音樂療法</li> <li>骨科座談會</li> </ul>	<ul> <li>拍攝各種 中醫護 理操作</li> <li>腦病科</li> <li>腦病科名中醫座談</li> <li>外科</li> <li>兒科、皮膚科</li> <li>總結</li> <li>頒發證書</li> </ul>





11

#### Implementation of the project in hospitals Pre-pilot drills & Inter-hospital visits



# ICWM Cancer Palliative Care in TMH



## Service Framework

- CM doctors round 7 days a week
  - On call phone support after off duty
- Use Herbal Medicine or Acupuncture
  - 50 CM formulas & 140 single CM items
  - Traditional acupuncture, auricular acupuncture, electro-acupuncture
- Cost: HKD 200/ day (waive in CSSA patient)
   Charge by CMCTR



# **Inclusion & Exclusion Criteria**

#### **Inclusion Criteria**

The patient meets ANY of the following criteria:

- a) Poor symptom control despite receiving a normal dosage of western medications.
- b) Low tolerance for the side effects of western medications or susceptible to significant adverse drug reactions.
- c) Patient intends to accept Chinese Medicine treatment.

#### **Exclusion Criteria**

The patient may not enter the program if ANY of the following apply:

- a) Symptoms with surgical indications.
- b) Unstable medical conditions as judged by the clinicians, e.g. sepsis with high fever, shock, respiratory failure, comatose.



# **Symptoms Covered**

- Pain
- Constipation
- Insomnia
- Lymphoedema
- Anorexia
- Lethargy



## **Case Selection**

- 1<sup>st</sup> screening by Ward Nurse
- 2<sup>nd</sup> screening by Ward Doctor
- Explain program to patient by Executive Assistant & CMP
- Written consent



# Ward Round & Case Conference

- Both Doctors & CM doctors have morning round on patient
- Senior round weekly
- Multidisciplinary meeting weekly
- Facilitate the collaboration of CM practitioners and all team members








# Examples of Problems Encountered




#### **Steps of Dissolve the Herbal Granules**



## **Acupuncture Safety Enhancement**

**Standardized procedure & Audit** 





# **Needles Disposal: Before**

#### Count the needles before disposal



#### Needle weight < 0.1g


Easy to bounce off from the sharp box











## Risk rating on Herb-Drug interactions (common-by drug)

No.	Drug classification	Drug	СМ	Risk level	Effects	Recommendations
			人參	Moderate	May <i>reduce</i> INR	Routine monitoring & weekly monitoring of INR until 2 weeks after stopping the CHM Countersigning for CM dose exceeding the recommended range when used with the drugs
1.	Anticoagulants	Warfarin	當歸	Moderate	May <i>increase</i> INR	Monitor INR 2-3 times/week. Countersigning for CM dose exceeding the recommended range when used with the drug(s)
			枸杞子	Low	May <i>increase</i> INR	Monitor INR weekly.
2.	Antihypertensive drug	Norvasc, Terazosin, Herbesser, Renitec, Hydralazine, Zestril, Adalat Retard	甘草	Low	May <b>reduce</b> the effectiveness of antihypertensive drug	Strict adherence to dose recommendation If CM dose exceeding the recommended range, countersigning when used with the drug(s).
3.	Calcium-channel blockers	Felodipine, with exception of amlodipine (Norvasc)	枳殼、枳實	Moderate	May <b>increase</b> the concentration of felodipine	If amlodipine is used, monitor BP.
	4. Corticosteriods	Corticosteriods All Drugs (Dexamethasone, Prednisolone, Becloforte) Oral/ IV	甘草	Moderate	May <i>increase</i> corticosteriod adverse effect	Regular BP, LFT&RFT monitoring Countersigning for CM dose exceeding the recommended range when used with the drug(s)
4.			麻黃	Moderate	May <i>increase</i> clearance of corticosteriods	CM dose cannot exceed recommended range.
5.	Cough preparations	Dextromethorphan (Phensedyl)	枳殼、枳實	Moderate	May <b>increase</b> the bioavailability of dextromethorphan	Not recommend.
6.	Diuretics	All Drugs (Lasix, Aldactone) Oral/ IV	甘草	Low	May <b>increase</b> risk of hypokalaemia and/or reduce effectiveness of the diuretic	Strict adherence to dose recommendation If CM dose exceeding the recommended range, countersigning when used with the drug(s).
		All drugs	人参	Moderate	May <i>lower</i> blood glucose level	Monitor blood glucose level
7.	Drugs used in diabetes	(Metformin, Gliclazide, Mixtard,	桑葉	Moderate	May <i>lower</i> blood glucose level	Monitor fasting H'stix.
		Insulin "long/short acting")	麻黄	Moderate	May increase blood glucose level	Monitor blood glucose level. CM dose cannot exceed recommended range.
8.	Eibinolytic drugs	Transamin	生薑	Low	May <i>increase</i> INR	Monitor bleeding tendency.
δ.	Fibinolytic drugs	Oral/ IV	黄芪	Low	May increase risk of bleeding	Monitor bleeding tendency.
9.	Hypnotics and anxiolytics	Midazolam (Dormicum)	丹参	Moderate	May <i>reduce</i> midazolam level	Titrate dose with clinical response



### Management of adverse effect and herb-drug interactions

		CMOs	CMPs	ICWM Nurses	Case Nurses
Before 🕇	Initial screening			$\checkmark$	
Enrollment ↓	2 <sup>nd</sup> screening	$\checkmark$	$\checkmark$		
1	Risk assessments	$\checkmark$	$\checkmark$	$\checkmark$	
	Review WMs & CMs	$\checkmark$	$\checkmark$	$\checkmark$	
After	Advocate relevant care suggestions	$\checkmark$	$\checkmark$	$\checkmark$	
Enrollment	Progress monitoring	$\checkmark$	$\checkmark$	$\checkmark$	$\checkmark$
$\checkmark$	Reporting	$\checkmark$			








## **ICWM Nurses**

Safeguard against the possible risks of Western and Chinese Medicine interactions

- Act as a bridge between • **CMOs and CMPs**
- Follow the tips for the ۲ monitoring and assessment from the protocol recommendations



Cue Cards



# Audits

Name	Compliance
Administration of oral Chinese Medicines	100%
Documentation of ICWM by CMP	96.5%
Filing & completion of ICWM medical records by all related staff	100%



## A glance of outcome



### **Program Statistics - TMH**

Period: 22/09/2014-29/02/2016

	Number of patient					
Initial screening	Screened	Enrolled	Recruitment rate	Discharged	Self-initiated drop out	Exit (Include dead cases)
1121	214	111	52%	28	7	72





Total unsuccessful enrollment= 103		
Not fulfilling inclusion & exclusion criteria	Number	
Poor patient's condition / Unable to give consent	25	
CMO did not recommend	18	57
Discharged / transferred	10	(55%)
Different expectations	4	. ,
Refused by Patient after EA explanation	Number	
Financial Difficulties	18	
Patients refused / No interest	11	
No Additional benefit	9	45
Relatives refused	3	
Patient would like to complete RT treatment first	3	(44%)
Patient has been receiving CM treatments provided	1	
by a private CM practitioner	Ţ	
Refused Patient after CMP assessment	Number	
Fear of taking CM	1	1
	Ŧ	(1%)
Hospital Authority Convention 2016 Integrated Chinese-Western Medicine Department of Clinical Oncology, To		
Vestern Medicine Depart		
Partment of Clinical Oncolor		Mark .
the second state of the se	len Mun Hospital	200

Period: from 22-09-2014 to 29-02-2016

xa

Hospital

Patient	status af	fter Enrol	Iment

(Final status in programme as at 29th Feb 2016)

Active in ward	4	
Discharged	28	
Exited	68	
Dead	11	
Total	111 patients	_
Al Authority Convention 2016 Integrated Chinese-Western Medicine Depa	artment of Clinical Oncology, Tuen Mun Hospital	KI

Patient F	Profile (111 patients)	Number	Percentage
Demographic	Age (mean, year of enrollment )	65	N/A
Characteristics	Gender, Male	63	57%
Characteristics	Gender, Female	48	43%
Daymont	No. of CSSA receivers	57	51%
Payment	No. of Self-financed patients	54	49%
	Pain 疼痛	70	63%
	Constipation 便秘	41	37%
Sumptom Control	Insomnia 失眠	21	19%
Symptom Control	Lymphoedema 水腫	37	33%
	Anorexia 食慾不振	59	53%
	Lethargy 怠倦嗜睡	72	65%
	Low tolerance for the side effects of western medications or susceptible to significant adverse drug reactions	20	18%
Inclusion Criteria	Poor symptom control despite receiving a normal dosage of western medications	33	30%
	Patient intends to receive Chinese Medicine (CM) treatment	101	91%
hital Authority Convention 2016 Integ	Prated Chinese-Western Medicine Department of Clinical Onco	blogy Tur	



Average LOS (day)	Average Waiting time (day)			
12.9 (Min 1, Max 63)	Screening to assessment	Enrolment to consultation		
	1.7	0.0		

Attend	lance	Number of t	reatment
In-patient (bed-days)	Out-patient average	Chinese Medicine	Acupuncture
Total: 1427	Around 5 per patient (Total 12 patients)	15.1 per patient	5.2 per patien

Number of incident	Number of complaint
0	0



#### **Summary of Outcome measurements** Week 1

<b>Indicators</b> # Higher scores indicate more severe symptom + Higher scores indicate higher functioning	Min - Max	Pre Day 0	Post Day 7	Results
Pain Score #	0-10	5.3	3.7*	Statistically significant
Lymphoedema circumference (mm)	N/A	320.9	318.2	
QOL Dyspnoea #	0-100	28.5	21.3	
QOL Pain #	0-100	48.6	36.0*	Statistically significant
QOL Insomnia #	0-100	45.9	37.7	
QOL Fatigue #	0-100	54.9	50.7	
QOL Appetite loss #	0-100	50.7	45.4	
QOL Nausea and vomiting #	0-100	12.8	12.8	
QOL Constipation #	0-100	51.2	37.2*	Statistically significant
QOL Psychical functioning $+$	0-93.3	23.0	20.8	
QOL Emotional functioning +	0-100	77.1	83.5*	Statistically significant
QOL Global health status $\pm$	0-100	53.2	53.4	
Hospital Authority Convention 2016 Integrated Chi	nese-Western Ma	Compar test, va	rison of Pre and Post b lues are mean, sample	y using Wilcoxon signed-rank size = 69
*P<0.05	- Wedic	Compar test, va	<sup>o</sup> gy, Tuen Mun Hospital	A CONTRACTOR



#### **Summary of Outcome measurements**

Week 3


<b>Indicators</b> # Higher scores indicate more severe symptom + Higher scores indicate higher functioning	Min - Max	Pre Day 0	Post Day 21	Results
Pain Score #	0-10	6.3	3.6*	Statistically significant
Lymphoedema circumference (mm)	N/A	N/A		
QOL Dyspnoea #	0-100	26.1	29.0	
QOL Pain #	0-100	60.1	27.5*	Statistically significant
QOL Insomnia #	0-100	59.4	34.8*	Statistically significant
QOL Fatigue #	0-100	61.4	46.4*	Statistically significant
QOL Appetite loss #	0-100	56.5	43.5	
QOL Nausea and vomiting #	0-100	17.4	17.4	
QOL Constipation #	0-100	52.2	26.1*	Statistically significant
QOL Psychical functioning $+$	0-93.3	19.4	24.1	
QOL Emotional functioning +	0-100	68.5	76.4	
QOL Global health status +	0-100	45.5	50.4	
QOL Global health status + Hospital Authority Convention 2016 Integrated Chin *P<0.05statistically significant Post: Day 21 / before discharge on exit	nese-Western Medic	Compa test, va	rison of Pre and Post b lues are mean, sample	y using Wilcoxon signed-rank e size = 23
*P<0.08 - statistically significant Post: Day 21 / before discharge or exit	A Contraction	arrent of Clinical Oncol	ogy, Tuen Mun Hospital	TXXX





#### **Satisfaction Survey**

#### Period: from 22-09-2014 to 29-02-2016





We would like to express our deep appreciation for the professional and kind supports offered by the following units and organizations:

- Yan Oi Tong The Chinese University of Hong Kong Chinese Medicine Centre for Training and Research (Tuen Mun)
- NTWC, Quality and Safety Division
- NTWC, Cluster Information Technology Section
- NTWC, Cluster Procurement & Materials Management Unit
- NTWC, Cluster Health Information Unit
- HAHO, Chinese Medicine Department
- HAHO, Nursing Services Department
- HAHO, Chief Pharmacist's Office







# Thank You!



